BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 33684514)

  • 1. GDNF signaling in subjects with minimal motor deficits and Parkinson's disease.
    Chu Y; Kordower JH
    Neurobiol Dis; 2021 Jun; 153():105298. PubMed ID: 33684514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of GDNF receptors GFRalpha1 and RET is preserved in substantia nigra pars compacta of aging Asian Indians.
    Alladi PA; Mahadevan A; Shankar SK; Raju TR; Muthane U
    J Chem Neuroanat; 2010 Sep; 40(1):43-52. PubMed ID: 20347960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term exposure to GDNF induces dephosphorylation of Ret, AKT, and ERK1/2, and is ineffective at protecting midbrain dopaminergic neurons in cellular models of Parkinson's disease.
    Mesa-Infante V; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Barroso-Chinea P
    Mol Cell Neurosci; 2022 Jan; 118():103684. PubMed ID: 34826608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do subjects with minimal motor features have prodromal Parkinson disease?
    Chu Y; Buchman AS; Olanow CW; Kordower JH
    Ann Neurol; 2018 Mar; 83(3):562-574. PubMed ID: 29420861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-Mortem Studies of Neurturin Gene Therapy for Parkinson's Disease: Two Subjects with 10 Years CERE120 Delivery.
    Chu Y; Kordower JH
    Mov Disord; 2023 Sep; 38(9):1728-1736. PubMed ID: 37544016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electroacupuncture Therapy Ameliorates Motor Dysfunction via Brain-Derived Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor in a Mouse Model of Parkinson's Disease.
    Pak ME; Ahn SM; Jung DH; Lee HJ; Ha KT; Shin HK; Choi BT
    J Gerontol A Biol Sci Med Sci; 2020 Mar; 75(4):712-721. PubMed ID: 31644786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GDNF Therapy: Can We Make It Work?
    Björklund A
    J Parkinsons Dis; 2021; 11(3):1019-1022. PubMed ID: 33935108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcranial alternating current stimulation rescues motor deficits in a mouse model of Parkinson's disease via the production of glial cell line-derived neurotrophic factor.
    Lee HJ; Jung DH; Jung YJ; Shin HK; Choi BT
    Brain Stimul; 2022; 15(3):645-653. PubMed ID: 35429660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease.
    Chu Y; Bartus RT; Manfredsson FP; Olanow CW; Kordower JH
    Brain; 2020 Mar; 143(3):960-975. PubMed ID: 32203581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
    Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
    Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the proto-oncogene Ret, a component of the GDNF receptor complex, persists in human substantia nigra neurons in Parkinson's disease.
    Walker DG; Beach TG; Xu R; Lile J; Beck KD; McGeer EG; McGeer PL
    Brain Res; 1998 May; 792(2):207-17. PubMed ID: 9593897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glial cell line-derived neurotrophic factor receptor Rearranged during transfection agonist supports dopamine neurons in Vitro and enhances dopamine release In Vivo.
    Mahato AK; Kopra J; Renko JM; Visnapuu T; Korhonen I; Pulkkinen N; Bespalov MM; Domanskyi A; Ronken E; Piepponen TP; Voutilainen MH; Tuominen RK; Karelson M; Sidorova YA; Saarma M
    Mov Disord; 2020 Feb; 35(2):245-255. PubMed ID: 31840869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GDNF signaling implemented by GM1 ganglioside; failure in Parkinson's disease and GM1-deficient murine model.
    Hadaczek P; Wu G; Sharma N; Ciesielska A; Bankiewicz K; Davidow AL; Lu ZH; Forsayeth J; Ledeen RW
    Exp Neurol; 2015 Jan; 263():177-89. PubMed ID: 25448159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing therapeutically more efficient Neurturin variants for treatment of Parkinson's disease.
    Runeberg-Roos P; Piccinini E; Penttinen AM; Mätlik K; Heikkinen H; Kuure S; Bespalov MM; Peränen J; Garea-Rodríguez E; Fuchs E; Airavaara M; Kalkkinen N; Penn R; Saarma M
    Neurobiol Dis; 2016 Dec; 96():335-345. PubMed ID: 27425888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of c-Ret, GFRalpha1, and GFRalpha2 in the substantia nigra pars compacta in a rat model of Parkinson's disease.
    Marco S; Saura J; Pérez-Navarro E; José Martí M; Tolosa E; Alberch J
    J Neurobiol; 2002 Sep; 52(4):343-51. PubMed ID: 12210101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective mechanisms by glial cell line-derived neurotrophic factor and cerebral dopamine neurotrophic factor against the α-synuclein accumulation in Parkinson's disease.
    Er S; Airavaara M
    Biochem Soc Trans; 2023 Feb; 51(1):245-257. PubMed ID: 36794783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RET expression does not change with age in the substantia nigra pars compacta of rhesus monkeys.
    Dass B; Kladis T; Chu Y; Kordower JH
    Neurobiol Aging; 2006 Jun; 27(6):857-61. PubMed ID: 15950322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reply to: "Bioinformatics and Immunohistochemistry Show Preserved Expression of GDNF Receptor RET in Parkinson's".
    Whone A
    Mov Disord; 2023 Jun; 38(6):1117-1118. PubMed ID: 37475613
    [No Abstract]   [Full Text] [Related]  

  • 20. Parkin cooperates with GDNF/RET signaling to prevent dopaminergic neuron degeneration.
    Meka DP; Müller-Rischart AK; Nidadavolu P; Mohammadi B; Motori E; Ponna SK; Aboutalebi H; Bassal M; Annamneedi A; Finckh B; Miesbauer M; Rotermund N; Lohr C; Tatzelt J; Winklhofer KF; Kramer ER
    J Clin Invest; 2015 May; 125(5):1873-85. PubMed ID: 25822020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.